Treatment with ATRA plus arsenic trioxide (ATO), which degrades the PML/RARα fusion protein, results in the differentiation of APL cells and is the only highly effective molecular targeted strategy for AML [24]. Here, PML is linked to acute promyelocytic leukemia.